<DOC>
	<DOCNO>NCT00109668</DOCNO>
	<brief_summary>QVAR standard press breath inhaler ( QVAR-MDI ) approve Food Drug Administration ( FDA ) use United States . The purpose study determine level asthma control compare safety effectiveness QVAR two different device , meter dose inhaler ( MDI ) breath operate inhaler ( BOI ) .</brief_summary>
	<brief_title>Evaluation Two Doses QVAR Versus Placebo Breath Operated Metered Dose Inhalers Moderate Asthmatic Adolescents Adults Stable Regimen Inhaled Corticosteroids</brief_title>
	<detailed_description>This investigation multicenter , randomize , placebo active control , double-blind , double-dummy , parallel-group study evaluate safety efficacy two dose QVAR-BOI adolescent adult .</detailed_description>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Male nonpregnant , nonnursing female least 12 year age screen visit . NOTE : Females childbearing potential may include practice acceptable method contraception least 2 month negative urine pregnancy test screen visit . Asthma ( FEV1 6085 % predict ) Ability perform acceptable reproducible spirometry Ability perform PEF determination Reversible bronchoconstriction verify great equal 12 % increase FEV1 follow inhalation albuterol . Historical reversibility allow Patients must stable regimen dailyinhaled corticosteroid low medium dose least 30 day prior screen . Otherwise healthy individual clinicallyacceptable medical history , physical examination , vital sign , 12 lead ECG , clinical laboratory parameter within acceptable range asthma patient . Nonsmoker least one year prior screen visit maximum smoke history tenpack year The patient must willing give write informed consent able adhere dose visit schedule . If applicable , parent guardian must also provide consent . Allergy sensitivity BDP ( beclomethasone dipropionate ) component formulation use CTM Patients demonstrate increase decrease FEV1 &gt; 20 % screen baseline visit . Patients require use &gt; 12 puff per day albuterol 3 consecutive day screen baseline visit . Patients unable use MDI without spacer device . ( Use spacers prohibit course study . ) Patients treated methotrexate , cyclosporin , gold cytotoxic agent control asthma concurrent condition within last 3 month . Patients receive escalate dos immunotherapy , oral immunotherapy short course ( rush ) immunotherapy rhinitis . Patients evidence oropharyngeal candidiasis . Exposure investigational drug within 30 day prior screen visit Require continuous treatment beta blocker ( administer route ) , MAO inhibitor , leukotriene modifier , tricyclic antidepressant , anticholinergic , inhale nedocromil cromolyn , nebulized therapy ( exclude sponsor provide albuterol MDI ) follow screen visit . Patients receive follow treatment meet follow condition within six week prior screen visit : *oral injectable corticosteroid ; *an upper respiratory tract infection and/or sinusitis associate exacerbation asthmatic symptom ; *emergency room treatment hospitalization asthmatic symptom Inability tolerate unwillingness comply require washout period applicable medication Treatment time lifethreatening asthmatic episode History presence nonasthmatic acute chronic lung disease History glaucoma , ocular hypertension cataract Presence systemic fungal , bacterial , viral parasitic infection and/or ocular herpes simplex Known suspect substance abuse ( e.g. , alcohol , marijuana , etc . ) Patients know HIV positive Unlikely compliant , take study medication direct , complete diary card , attend schedule clinic visit require .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>